Many of the winners at this year’s CPhI Pharma Awards, held on November 5 at the 2019 CPhI Worldwide meeting in Frankfurt, Germany, offer significant expertise in inhaled and nasal drug delivery, including Lonza, which was named Pharma Service Company of the Year. Lonza Capsugel was also a finalist in the Excellence in Pharma: Formulation category for the Capsugel Zephyr DPI capsule portfolio, which was launched in May 2019. Lonza acquired Capsugel in 2017.
The winner of the Excellence in Pharma: Formulation award was Nanoform, which was also a sponsor of the this year’s awards. The company won for its Controlled Expansion of Supercritical Solutions (CESS) nanoparticle manufacturing process, which the Nanoform says “enables the creation of nanoparticles small enough to penetrate into the deep lung but also allows us the ability to tailor particle size for specific lung delivery requirements.”
Nanoform CEO Edward Hæggström commented, “We are delighted to have received this prestigious award. It is a fantastic testament to the hard work of the Nanoform team and their ability to deliver high quality nanonization services that help pharma companies develop life-changing medicines.”
Respiratory R&D specialist Nanopharm, which was recently acquired by Aptar, won for Pharma Excellence: Contract Services and Outsourcing for its SmartTrack integrated solution approach. Aptar Pharma President Gael Touya commented, “We are delighted that Nanopharm’s SmartTrack was recognized by the industry for its innovative approach. This reinforces the Aptar Pharma Services mission to further help customers during their entire product lifecycle of the drug product and deliver them a complete solution.”
Nanopharm CEO Jag Shur said, “This award marks a significant milestone for our SmartTrack platform, and signifies the R&D endeavor at Nanopharm to develop alternative bioequivalence strategies for OINDPs. I would like to thank our employees, clients and partners in this success.”
Other winners included Medpharm, which offers formulation and characterization services for a wide range of OINDPs and which won in the Excellence in Pharma: Analysis, Testing, and Quality Control category, and Phillips-Medisize in the Drug Delivery Devices category, where it was recognized for its connected health platform. Phillips-Medisize is partnered with Aerami Therapeutics (formerly Dance Biopharm) on development of a connected version of Aerami’s soft mist insulin inhaler.
Read the Nanoform press release.
Read the Aptar press release.
